Welcome to our dedicated page for MBX Biosciences SEC filings (Ticker: MBX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The MBX Biosciences, Inc. (Nasdaq: MBX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a clinical-stage biopharmaceutical company and emerging growth company, MBX uses filings such as Forms S-1, 10-K, 10-Q, and 8-K to describe its Precision Endocrine Peptide™ (PEP™) platform, clinical programs, risk factors, and capital-raising activities.
In its S-1 registration statement, MBX outlines its focus on novel precision peptide therapies for endocrine and metabolic disorders and details key product candidates, including canvuparatide (MBX 2109) for chronic hypoparathyroidism, imapextide (MBX 1416) for post-bariatric hypoglycemia, and MBX 4291 for obesity. Subsequent 8-K filings report material events such as topline results from the Phase 2 Avail™ trial of canvuparatide, initiation of the Phase 1 trial of MBX 4291, public equity offerings, and changes in board and committee roles.
Through this page, users can review MBX’s periodic financial reports, which discuss research and development spending, cash and marketable securities, and expectations about funding operations, as well as prospectus materials that describe intended uses of offering proceeds. Form 8-K filings also summarize key clinical data, trial designs, and future development plans for the company’s programs.
Stock Titan enhances these filings with AI-powered summaries that highlight the main points of lengthy documents, helping readers quickly understand topics such as clinical results, financing terms, and governance updates. Real-time updates from EDGAR, along with structured access to material event reports and registration statements, make this page a central resource for analyzing MBX’s regulatory and financial disclosures.
MBX Biosciences granted director Laurie Stelzer stock options covering 32,000 shares of common stock on January 20, 2026. These options have an exercise price of $43.14 per share and are held as a direct ownership position.
One-third of the underlying shares will vest and become exercisable on January 20, 2027, the first anniversary of the grant date, with the remaining two-thirds vesting monthly over the following two years, subject to her continued service. After this grant, she beneficially owns 32,000 derivative securities linked to MBX Biosciences common stock.
MBX Biosciences director files initial ownership report with no holdings
MBX Biosciences, Inc. director Laurie Stelzer filed an initial Form 3 ownership report related to an event dated 01/20/2026. The filing identifies Stelzer as a director of MBX Biosciences and indicates that no non-derivative or derivative securities of the company are beneficially owned. The remarks section explicitly states that no securities are beneficially owned, confirming there are currently no reported MBX Biosciences shares or derivative instruments held by this reporting person.
MBX Biosciences, Inc. announced that its board of directors has appointed Laurie Stelzer as a new independent director, effective January 20, 2026. She was designated as a Class I director and will serve until the company’s 2028 annual meeting of stockholders, then continue until a successor is elected and qualified or until an earlier departure.
With her addition, the board size is set at eight directors, and she fills an existing vacancy. As a non-employee director, she will receive the same compensation as other non-employee directors under the company’s disclosed director compensation policy, and she will enter into the standard indemnification agreement used for other directors.
Ms. Stelzer has also been appointed to serve as a member and chairperson of the Audit Committee, replacing Ed Mathers on that committee, and will serve on the Compensation Committee. The compositions of the Nominating and Corporate Governance Committee and the Science and Medicine Committee remain unchanged.
MBX Biosciences Inc reported that BlackRock, Inc. has filed a Schedule 13G showing a significant passive ownership position in its common stock. As of the event date of 12/31/2025, BlackRock beneficially owned 2,271,161 MBX shares, representing 5.1% of the outstanding common stock.
BlackRock reports sole voting power over 2,244,877 shares and sole dispositive power over 2,271,161 shares, with no shared voting or dispositive power. The filing explains that this ownership is aggregated from certain BlackRock business units, and that various underlying clients have rights to dividends or sale proceeds, with no single client holding more than five percent of MBX’s outstanding common shares.
BlackRock certifies that the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of MBX Biosciences.
MBX filed a Form 144 notice of proposed sale of restricted stock. The filing covers the planned sale of 30,864 shares of common stock through Fidelity Brokerage Services LLC, with an aggregate market value of $1,102,991.13, to be sold on or about 01/12/2026 on the NASDAQ market. The filing notes that 44,902,302 shares of common stock were outstanding.
The shares to be sold were recently acquired by exercising stock options granted on 09/12/2024, 01/31/2024, and 09/01/2020. On 01/12/2026, the filer acquired 4,323, 9,905, and 16,636 common shares, respectively, paying cash upon exercise. By signing the notice, the seller represents they are not aware of any undisclosed material adverse information about the issuer’s current or prospective operations.
MBX Biosciences reported preliminary unaudited cash, cash equivalents and marketable securities of
MBX Biosciences, Inc. (MBX) disclosed a new equity award to a director. On 11/22/2025, the director received a stock option to purchase 8,000 shares of common stock at an exercise price of $27.08 per share, reported as a derivative security in Table II.
The option covers 8,000 underlying shares of common stock and is held directly by the reporting person. According to the footnote, the grant will vest in equal monthly installments over a one-year period from November 6, 2025, conditioned on the non-employee director continuing to provide services to the company.
MBX Biosciences (MBX) reported a director stock option grant. On November 6, 2025, the director received 100,000 stock options with an exercise price of $24.74. The options vest in equal monthly installments over one year from the grant date, contingent on continued service. The award expires on November 5, 2035. Following the grant, the reporting person held 100,000 derivative securities, reported as Direct (D) ownership.
MBX Biosciences filed an S-3 shelf registration to offer, issue and sell up to $400,000,000 of securities from time to time. The filing also includes a sales agreement prospectus supplement for an at-the-market program to sell up to $150,000,000 of common stock through Jefferies LLC, which is included within the $400,000,000 shelf capacity.
Sales may occur on a continuous or delayed basis, with specific terms set in future supplements. The company states that net proceeds will be used for development of clinical-stage programs, discovery R&D, additional clinical development, and general corporate purposes, including working capital and capital expenditures.
MBX’s common stock trades on the Nasdaq Global Select Market under “MBX.” The last reported sale price was $20.62 per share on November 4, 2025. Shares outstanding were 44,715,498 as of September 30, 2025.
MBX Biosciences (MBX) filed its Q3 2025 10‑Q, highlighting a stronger balance sheet after a September underwritten offering. The company reported a net loss of $21.6 million for the quarter as operating expenses rose with pipeline advancement. Research and development was $19.3 million and general and administrative was $4.7 million, reflecting continued clinical activity.
Liquidity improved materially: cash, cash equivalents and marketable securities were $391.7 million as of September 30, 2025, supported by the September 2025 offering of 11,108,055 shares at $18.00 for $187.4 million in net proceeds. Total assets were $400.1 million and stockholders’ equity was $387.5 million.
Pipeline updates: canvuparatide met the primary endpoint in Phase 2; the company plans End of Phase 2 interactions in Q1 2026 and a Phase 3 start in Q3 2026. MBX 4291 is in Phase 1 for obesity, and imapextide showed positive Phase 1 results with a Phase 2a in progress. Shares outstanding were 44,715,498 as of September 30, 2025; 44,902,302 as of November 3, 2025.
FAQ
What is the current stock price of MBX Biosciences (MBX)?
What is the market cap of MBX Biosciences (MBX)?
